SCHEMBL5136469

SCHEMBL5136469

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1c(OC)cccc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CASR P41180 1/20 0.40
TLR8 Q9NR97 1/20 0.40
TSHR P16473 5/20 0.38
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 5/20 0.38
HPGD P15428 5/20 0.38
HSD17B10 Q99714 5/20 0.38
CYP3A4 P08684 4/20 0.38
PDE4B Q07343 1/20 0.38
C5AR1 P21730 1/20 0.38
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135095 0.90 BCHE (0.47) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5136939 0.89 CRHR1 (0.42) TP53GAASMN1; SMN2CASRTSHR
SCHEMBL5136790 0.88 ALOX5 (0.42) TP53GAASMN1; SMN2CASRTLR8
SCHEMBL5069962 0.87 BCHE (0.45) CASRTSHRC5AR1BCHEACHE
SCHEMBL5134701 0.86 KDM4E (0.39) TP53TSHRKDM4EALDH1A1HPGD
SCHEMBL5136698 0.86 ALDH1A1 (0.39) TP53TSHRKDM4EALDH1A1HPGD
SCHEMBL5137330 0.86 BCHE (0.43) CASRC5AR1BCHEACHE
SCHEMBL5070097 0.86 TP53 (0.48) TP53GAASMN1; SMN2TSHRKDM4E
SCHEMBL5134803 0.85 BCHE (0.43) C5AR1BCHEACHE
SCHEMBL5135661 0.85 TP53 (0.41) TP53GAASMN1; SMN2CASRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed